Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTYM8DJ)

• DTT Name: Ectonucleoside triphosphate diphosphohydrolase 1 (CD39)
• Synonyms: NTPDase1; NTPDase 1; Lymphoid cell activation antigen; Ecto-nucleotidase CD-39; Ecto-apyrase; Ecto-ATPase 1; Ecto-ATPDase 1; Ecto-ATP diphosphohydrolase 1; Ecto-ATP diphosphohydrolase; CD39 antigen; ATPDase
• Gene Name: ENTPD1
• DTT Type: Clinical trial target; [1]
• BioChemical Class: Acid anhydride hydrolase
• UniProt ID: ENTP1_HUMAN
• TTD ID: T58298
• EC Number: EC 3.6.1.5
• Sequence:
  MEDTKESNVKTFCSKNILAILGFSSIIAVIALLAVGLTQNKALPENVKYGIVLDAGSSHT
  SLYIYKWPAEKENDTGVVHQVEECRVKGPGISKFVQKVNEIGIYLTDCMERAREVIPRSQ
  HQETPVYLGATAGMRLLRMESEELADRVLDVVERSLSNYPFDFQGARIITGQEEGAYGWI
  TINYLLGKFSQKTRWFSIVPYETNNQETFGALDLGGASTQVTFVPQNQTIESPDNALQFR
  LYGKDYNVYTHSFLCYGKDQALWQKLAKDIQVASNEILRDPCFHPGYKKVVNVSDLYKTP
  CTKRFEMTLPFQQFEIQGIGNYQQCHQSILELFNTSYCPYSQCAFNGIFLPPLQGDFGAF
  SAFYFVMKFLNLTSEKVSQEKVTEMMKKFCAQPWEEIKTSYAGVKEKYLSEYCFSGTYIL
  SLLLQGYHFTADSWEHIHFIGKIQGSDAGWTLGYMLNLTNMIPAEQPLSTPLSHSTYVFL
  MVLFSLVLFTVAIIGLLIFHKPSYFWKDMV
• Function: Could also be implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. Hydrolyzes ATP and ADP equally well. In the nervous system, could hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission.
• KEGG Pathway:
  Purine metabolism (hsa00230)
  Pyrimidine metabolism (hsa00240)
  Epstein-Barr virus infection (hsa05169)
• Reactome Pathway:
  Purinergic signaling in leishmaniasis infection (R-HSA-9660826)
  Phosphate bond hydrolysis by NTPDase proteins (R-HSA-8850843)
• BioCyc Pathway: MetaCyc:HS06471-MON

Molecular Interaction Atlas (MIA) of This DTT

3 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IPH5201	DMFEI6T	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
SRF617	DMTK1BV	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
TTX-030	DM8H2AG	Lymphoma	2A80-2A86	Phase 1	[4]

2 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PSB-0963	DMBDVJ1	Discovery agent	N.A.	Investigative	[5]
PSB-6426	DMJ9ML8	Discovery agent	N.A.	Investigative	[1]

References

• [1] Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide. J Med Chem. 2008 Aug 14;51(15):4518-28.
• [2] ClinicalTrials.gov (NCT04261075) IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of Surface oncology.
• [4] Clinical pipeline report, company report or official report of AbbVie.
• [5] Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.